Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Transformation induced dependency of the normally non-vital RNA helicase DDX3X provides a novel therapeutic strategy in lung cancer

FY 2015-16

Summary
Lung Cancer is the leading cause of cancer death worldwide, mainly due to the lack of effective drugs available. One strategy to improve long-term patient outcomes is to discover new targetable genes that lung cancer cells are dependent on in order to selectively kill these cells. Recently, a large-scale screen of ~200,000 chemical compounds revealed LCS3 (or lung cancer screen 3), a compound that demonstrated selective toxicity against cancer cells and not normal cells. A target of LCS3 has recently been identified as DDX3X, a protein whose function has never been investigated in lung cancer. Interestingly, this protein is expressed in normal and lung cancer cells in the same capacity (similar amounts and non-mutated) which is quite different from the common strategy of looking for genes that are mutated or expressed in much higher or lower amounts compared to normal. This projects focus is to first determine if lung cancer cells are dependent on DDX3X for survival by trying to rescue lung cancer cells from death due to LCS3 treatment by means of increasing the amount of DDX3X in the cells. If successful, it would suggest that lung cancer cells are dependent on DDX3X. Next, I would experimentally induce cancer progression in normal lung cells through mutated genes transformation or tobacco carcinogen treatment to investigate whether these cells become dependent on DDX3X for survival. Lastly, I aim to identify why cells are dependent on DDX3X by looking at effects on all other genes and proteins when DDX3X is inhibited in cancer cells compared to normal cells. If this gene can be proven to be vital to lung cancer survival it could open up a whole new area of drug development that ultimately could lead to more effective treatment for lung cancer patients.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
350025
Name
Calder Jack B
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Transformation induced dependency of the normally non-vital RNA helicase DDX3X provides a novel therapeutic strategy in lung cancer
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Dependency; Ddx3x; Dead-Box Helicase; Drug Discovery And Characterization; High Throughput Drug Screen; Lung Tumorigenesis; Non-Small Cell Lung Cancer; Phenotypic Based Screening; Small-Molecule Inhibitors; Target Validation
Abstract
Lung Cancer is the leading cause of cancer death worldwide, mainly due to the lack of effective drugs available. One strategy to improve long-term patient outcomes is to discover new targetable genes that lung cancer cells are dependent on in order to selectively kill these cells. Recently, a large-scale screen of ~200,000 chemical compounds revealed LCS3 (or lung cancer screen 3), a compound that demonstrated selective toxicity against cancer cells and not normal cells. A target of LCS3 has recently been identified as DDX3X, a protein whose function has never been investigated in lung cancer. Interestingly, this protein is expressed in normal and lung cancer cells in the same capacity (similar amounts and non-mutated) which is quite different from the common strategy of looking for genes that are mutated or expressed in much higher or lower amounts compared to normal. This projects focus is to first determine if lung cancer cells are dependent on DDX3X for survival by trying to rescue lung cancer cells from death due to LCS3 treatment by means of increasing the amount of DDX3X in the cells. If successful, it would suggest that lung cancer cells are dependent on DDX3X. Next, I would experimentally induce cancer progression in normal lung cells through mutated genes transformation or tobacco carcinogen treatment to investigate whether these cells become dependent on DDX3X for survival. Lastly, I aim to identify why cells are dependent on DDX3X by looking at effects on all other genes and proteins when DDX3X is inhibited in cancer cells compared to normal cells. If this gene can be proven to be vital to lung cancer survival it could open up a whole new area of drug development that ultimately could lead to more effective treatment for lung cancer patients.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Calder, Jack B
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~